CureVac AG, a biopharmaceutical company that develops messenger RNA (mRNA) therapeutics. It offers RNActive, which are mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases; RNArt molecular therapies that are designed to trigger the body's own production of therapeutic proteins; and RNAdjuvant RNA encoded antibodies. The company also researches and develops active ingredients for the treatment of cancer, as well as for protection against infectious diseases; and RNActive-based rabies vaccines. The company was founded in 2000 and is based in Tubingen, Germany.
Founded in 2000
CureVac AG Appoints Pierre Kemula as Chief Financial Officer
Oct 11 16
CureVac AG announced the appointment of Pierre Kemula as Chief Financial Officer. Mr. Kemula will join CureVac's management board and will be responsible for leading the company's financial and capital markets activities. Mr. Kemula joins CureVac after serving as Chief Financial Officer of Pixium Vision. During his tenure as CFO of Pixium Vision, Mr. Kemula was instrumental in the company's successful initial public offering on Euronext. Mr. Kemula began his career in consulting, with successful tenures at Roland Berger, Kea & Partners, Gemini Consulting and KPMG. He received his degree in Management Sciences from the London School of Economics in the United Kingdom.
CureVac AG Presents at 9th DVFA Life Science Conference, Jun-14-2016 02:05 PM
Jun 13 16
CureVac AG Presents at 9th DVFA Life Science Conference, Jun-14-2016 02:05 PM. Venue: DVFA Center, Mainzer Landstraße 37-39, 60329 Frankfurt am Main, Germany. Speakers: Franz-Werner Haas, Chief Corporate Officer.
CureVac Announces New Board Appoints
Mar 30 16
CureVac announced the expansion of its external Scientific Advisory Board (SAB). CureVac'sScientific Advisory Board includes the following experts across the company's core therapeutic categories: Prof. Carol J. Baker, MD, Professor of Pediatrics, Molecular Virology & Microbiology, Baylor College of Medicine, Houston; past-chair of the Advisory Committee on Immunization Practices (ACIP), president of the Infectious Diseases Society of America and the National Foundation for Infectious Diseases; Prof. Nina Bhardwaj, MD, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City; elected member of the American Society of Clinical Investigation and the American Association of Physicians; senior editor of the AACR Cancer Immunology Research journal; Ralf Clemens, MD, Chair of the SAB, former Vice President/Senior Vice President GSK Biologicals, Novartis Vaccines and Takeda Vaccines; advisor to the Bill & Melinda Gates Foundation and to the Africa Research Excellence Fund (AREF); member of CureVac's Supervisory Board; Michel De Wilde, PhD, member of the Board of Directors of the Infectious Disease Research Institute (IDRI) and of VBI; former Senior Vice President R&D at Sanofi Pasteur and Vice President Research GSK Biologicals; Prof. Dirk Jäger, MD, Director of Medical Oncology at the University Hospital of Heidelberg, Germany; leader of the research group "Applied Tumor Immunity" at the German Cancer Research Center; Prof. Karim Fizazi, MD, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France; President of the French Study Group of Carcinomas of Unknown Primary and associate editor of the European Journal of Cancer; Christopher Karp, MD, Director of Global Health Discovery & Translational Sciences at the Bill & Melinda Gates Foundation; Prof. Michael P. Manns, MD, Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany; Prof. Stanley Plotkin, MD, Emeritus Professor of the Wistar Institute and the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University; editor of the standard textbook "Vaccines"; Jean-Paul Prieels, PhD, Member of the Board of various Biotech companies including DNAlytics and Vaximm; former Senior Vice President R&D at GSK Biologicals; Prof. Hans-Georg Rammensee, PhD, Head of the Department of Immunology at the University of Tübingen, Germany; George R. Siber, MD, Chief Scientific Officer, ClearPath Vaccines Company and former Executive Vice President of Wyeth Pharma, CSO of Wyeth Vaccines and Director of the Massachusetts Biologic Laboratories; Prof. Daniel Speiser, MD, head of clinical tumor biology and immunotherapy group, Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland; Prof. Xiao-Ning Xu, MD, PhD, Chair in Human Immunology at the Imperial College London; previously Head of Novartis Vaccines Research China; Prof. Fred Zepp, MD, Medical Director and Chairman of the Department of Pediatrics, University Medical Center of the Johannes Gutenberg-University Mainz, Germany; past president of the German Society of Pediatrics and Adolescent Medicine; member of the STIKO at the Robert Koch Institute; and Gerd Zettlmeissl, PhD, Chairman Hilleman Laboratories, Board of Directors of Aeras and board member of various Biotech companies; former Managing Director of Chiron Behring and Chief Executive Officer of Intercell.